Americafirst Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Americafirst Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-60,901	Closed	-$129K	–	286
2016 Q4	$129K	Sell	60,901 -490,903	-89%	-$1.37M	0.14%	135
2016 Q3	$1.85M	Buy	+551,804	New	+$1.75M	1.54%	4
2015 Q4	–	Sell	-96,067	Closed	-$483M	–	218
2015 Q3	$483M	Buy	96,067 +945	+1%	+$5.42K	0.28%	125
2015 Q2	$612K	Buy	+95,122	New	+$637K	0.33%	126
2015 Q1	–	Sell	-67,971	Closed	-$524M	–	390
2014 Q4	$524M	Sell	67,971 -10,717	-14%	-$84.8K	0.25%	151
2014 Q3	$588M	Buy	+78,688	New	+$731K	0.29%	154

Other funds holding PDLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Americafirst Capital Management's PDLI Position: Q1 2017 in Review

Americafirst Capital Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2017, closing a stake of 60,901 shares — an estimated $129K sold.

Americafirst Capital Management first reported a position in PDLI in Q3 2014 and held it in 6 quarters. The position peaked at $588M in Q3 2014. 174 funds tracked by Wall St. Rank hold PDLI as of Q1 2017.

Americafirst Capital Management reported no remaining PDL BioPharma, Inc. position as of Q1 2017 after selling out during the quarter.
Americafirst Capital Management sold 60,901 PDL BioPharma, Inc. shares in Q1 2017, an estimated $129K.
Americafirst Capital Management first reported a position in PDL BioPharma, Inc. in Q3 2014 and held it in 6 quarters.
Americafirst Capital Management's PDL BioPharma, Inc. position peaked at $588M in Q3 2014.
174 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2017.

Based on Americafirst Capital Management's 13F filing for Q1 2017, filed 17 Apr 2017.